HTS Screen Identifies CGP7930, a Known GABA-B Modulator, as a Potent Activator of the Cardiac Mitochondrial Calcium Uniporter
- Researchers screened a library of 1,280 known bioactive compounds in search of pharmacological activators of the mitochondrial calcium uniporter complex (MCUc), a target for which potent, selective agonists have been scarce.
- The screen identified CGP7930 — a compound previously characterized as a GABA-B receptor allosteric modulator — as a potent activator of mitochondrial calcium uptake, highlighting a drug-repurposing angle for a difficult target.
- Mechanistic follow-up showed the activating effect depends on MICU1, a key regulatory subunit of the uniporter complex, pointing to a specific mode of action rather than a nonspecific membrane effect.
- Enhanced mitochondrial calcium entry translated into improved cardiac contractile bioenergetics, suggesting relevance to conditions involving impaired heart energy metabolism.
- The work provides a valuable pharmacological tool compound and a starting point for developing more selective next-generation MCU activators.
CGP7930 landing as an MCU activator is the kind of hit that's simultaneously a gift and a headache. MICU1-dependence is the real finding here — it means the compound isn't just permeabilizing membranes or brute-forcing the pore, it's engaging a regulatory interface, which is exactly what you want if you're hunting for a selectivity handle to build SAR around. But this molecule already has a day job as a GABA-B PAM, so before I'd touch it as a lead I'd want a counter-screen and a clean SAR series that walks GABA-B affinity down while holding MCU activation up — classic polypharmacology triage, not a bonus. As a repurposed known compound it buys you PK/tox data, not real IP or optimized potency; it's a starting point, not a lead. Given how thin the MCU tool-compound cupboard has been, though, any validated chemical matter here is worth chasing.